Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Volume: 39, Issue: 15_suppl, Pages: 4100 - 4100
Published: May 20, 2021
Abstract
4100 Background: Checkpoint inhibition with anti-PD1 is able to elicit objective response rates (ORR) of ̃ 20% in patients with advanced hepatocellular carcinoma (aHCC) but molecular biomarkers predicting response remain unknown. Here, we define biomarkers of response and primary resistance to anti-PD1 in aHCC by analyzing molecular features prior to systemic therapy. Methods: Through an international consortium of 13 referral centers, we...
Paper Details
Title
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Published Date
May 20, 2021
Journal
Volume
39
Issue
15_suppl
Pages
4100 - 4100
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History